135 related articles for article (PubMed ID: 33386761)
1. Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions.
Bracchi RC; Tseliou F; Copeland L; Routledge PA; Thomas A; Woods F; Adams A; Walker J; Jadeja M; Atkinson MD; Ashfield-Watt P
Br J Clin Pharmacol; 2021 Aug; 87(8):3344-3348. PubMed ID: 33386761
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
3. Assessing and further developing age-appropriate information for young people about reporting suspected adverse drug reactions.
Bioletti L; ; Woodward C; Jadeja M; Hawcutt DB
Br J Clin Pharmacol; 2024 Mar; 90(3):863-870. PubMed ID: 37990602
[TBL] [Abstract][Full Text] [Related]
4. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.
Krska J; Anderson C; Murphy E; Avery AJ
Drug Saf; 2011 May; 34(5):429-36. PubMed ID: 21513365
[TBL] [Abstract][Full Text] [Related]
5. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.
McLernon DJ; Bond CM; Hannaford PC; Watson MC; Lee AJ; Hazell L; Avery A;
Drug Saf; 2010 Sep; 33(9):775-88. PubMed ID: 20701410
[TBL] [Abstract][Full Text] [Related]
7. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain.
Fortnum H; Lee AJ; Rupnik B; Avery A;
J Clin Pharm Ther; 2012 Apr; 37(2):161-5. PubMed ID: 21592158
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reaction reporting by community pharmacists-The barriers and facilitators.
Hughes ML; Weiss M
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1552-1559. PubMed ID: 31131966
[TBL] [Abstract][Full Text] [Related]
9. Information for children and young people about reporting suspected adverse drug reactions.
Hawcutt DB; Jadeja M; Bhoombla N; Smith S; McWilliam SJ
Arch Dis Child; 2022 Jul; 107(7):681-685. PubMed ID: 35292430
[TBL] [Abstract][Full Text] [Related]
10. Views of British community pharmacists on direct patient reporting of adverse drug reactions (ADRs).
Krska J
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1130-3. PubMed ID: 22729956
[TBL] [Abstract][Full Text] [Related]
11. Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator.
Deslandes PN; Bracchi R; Jones K; Haines KE; Carey E; Adams A; Walker J; Thomas A; Routledge PA
Br J Clin Pharmacol; 2022 Aug; 88(8):3829-3836. PubMed ID: 35322450
[TBL] [Abstract][Full Text] [Related]
12. Parental reporting of adverse drug reactions in South Africa: An online survey.
Pillay S; Mulubwa M; Viljoen M
Afr J Prim Health Care Fam Med; 2021 Sep; 13(1):e1-e8. PubMed ID: 34636609
[TBL] [Abstract][Full Text] [Related]
13. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.
McLernon DJ; Bond CM; Lee AJ; Watson MC; Hannaford PC; Fortnum H; Krska J; Anderson C; Murphy E; Avery A;
Pharmacoepidemiol Drug Saf; 2011 May; 20(5):523-31. PubMed ID: 21328634
[TBL] [Abstract][Full Text] [Related]
14. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Anderson C; Krska J; Murphy E; Avery A;
Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
[TBL] [Abstract][Full Text] [Related]
15. The involvement of nurses in reporting suspected adverse drug reactions: experience with the meningococcal vaccination scheme.
Ranganathan SS; Houghton JE; Davies DP; Routledge PA
Br J Clin Pharmacol; 2003 Dec; 56(6):658-63. PubMed ID: 14616426
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group.
Bhoombla N; Preston J; Ainsworth J; Bird H; Jadeja M; King C; Hawcutt DB
Paediatr Drugs; 2020 Jun; 22(3):335-341. PubMed ID: 32253722
[TBL] [Abstract][Full Text] [Related]
17. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J
Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
[TBL] [Abstract][Full Text] [Related]
18. Reported paediatric adverse drug reactions in the UK 2000-2009.
Hawcutt DB; Mainie P; Riordan A; Smyth RL; Pirmohamed M
Br J Clin Pharmacol; 2012 Mar; 73(3):437-46. PubMed ID: 21988288
[TBL] [Abstract][Full Text] [Related]
19. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
[TBL] [Abstract][Full Text] [Related]
20. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
Klein K; Hazell L; Stolk P; Shakir S
Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
